Yahoo
NYSE - BOATS Real Time Price USD

Medtronic plc (MDT)

78.30 -1.70 (-2.13%)
At close: May 4 at 4:00:02 PM EDT
78.52 +0.22 (+0.28%)
Overnight: 1:47:30 AM EDT
Trade MDT on Coinbase
Chart Range Bar
Loading chart for MDT
Chart does not reflect overnight price.

News headlines Medtronic (MDT) faces challenges with a 2.13% declinein shares and an upcoming earnings report. Analysts forecast Q2 EPS of $1.58and revenue of $9.66 billion, alongside concerns about industry competition and a low Zacks Rank of #4 (Sell).

Medtronic (MDT) faces challenges with a 2.13% declinein shares and an upcoming earnings report. Analysts forecast Q2 EPS of $1.58and revenue of $9.66 billion, alongside concerns about industry competition and a low Zacks Rank of #4 (Sell).

Updated 24m ago · Powered by Yahoo Scout
  • Previous Close 80.00
  • Open 79.47
  • Bid --
  • Ask --
  • Day's Range 78.29 - 79.59
  • 52 Week Range 78.29 - 106.33
  • Volume 9,072,319
  • Avg. Volume 8,702,091
  • Market Cap (intraday) 100.528B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) 22.31
  • EPS (TTM) 3.51
  • Earnings Date Jun 3, 2026
  • Forward Dividend & Yield 2.84 (3.55%)
  • Ex-Dividend Date Mar 27, 2026
  • 1y Target Est 108.00

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

www.medtronic.com

95,000

Full Time Employees

April 25

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview: MDT

Trailing total returns as of 5/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDT
17.82%
S&P 500 (^GSPC)
5.19%

1-Year Return

MDT
4.79%
S&P 500 (^GSPC)
26.63%

3-Year Return

MDT
3.31%
S&P 500 (^GSPC)
77.31%

5-Year Return

MDT
29.01%
S&P 500 (^GSPC)
72.90%

Earnings Trends: MDT

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 9.02B
Earnings 1.75B

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B

Analyst Insights: MDT

View More

Analyst Price Targets

90.00
108.00 Average
78.30 Current
121.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/22/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 104 -> 90

Statistics: MDT

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    102.71B

  • Enterprise Value

    122.40B

  • Trailing P/E

    22.35

  • Forward P/E

    13.11

  • PEG Ratio (5yr expected)

    1.40

  • Price/Sales (ttm)

    2.90

  • Price/Book (mrq)

    2.10

  • Enterprise Value/Revenue

    3.45

  • Enterprise Value/EBITDA

    13.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.00%

  • Return on Assets (ttm)

    4.57%

  • Return on Equity (ttm)

    9.39%

  • Revenue (ttm)

    35.48B

  • Net Income Avi to Common (ttm)

    4.61B

  • Diluted EPS (ttm)

    3.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.38B

  • Total Debt/Equity (mrq)

    57.06%

  • Levered Free Cash Flow (ttm)

    4.07B

Compare To: MDT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: MDT

Fair Value

78.30 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: MDT

View More
  • US Large Cap Pick List - April 2026

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

  • Reiterating BUY on price weakness

    With operational headquarters in Minneapolis, Medtronic is one of the world's largest medical technology and solutions companies. Its devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. The company is a component of the S&P 500.

    Rating
    Price Target
  • The war with Iran enters its sixth week. As well, major new inflation data is

    The war with Iran enters its sixth week. As well, major new inflation data is due out this week and earnings season is just ahead, with banks starting to report on April 14. Last week, the Dow Jones Industrial Average gained 1%, while the S&P 500 and the Nasdaq both rose 2%. Year to date, all three indices are showing losses, with the Dow, down 3%, the S&P lower by 4%, and the Nasdaq off by 6%. On the earnings calendar, there are a few scattered reports this week. Levi Strauss reports on Tuesday; and Shell, Delta Air Lines, and Constellation Brands on Wednesday. The new earnings season unofficially kicks off on April 14, when several of the country's big banks report. On the economic calendar, new data on Durable Goods Orders is due on Tuesday; the minutes from the Fed's May rate meeting on Wednesday; Personal Consumption Expenditures (inflation) and the final revision of GDP on Thursday; and the Consumer Price Index (more on inflation) on Friday. The timing of the inflation data is off plan. PCE will reflect February data while CPI will represent March. The impact of the war in Iran is starting to show up in economic forecasts. Gas prices jumped another three cents and are at an average of $3.99 per gallon for regular gas. The Atlanta Fed GDPNow now forecasts 1.6% growth for 1Q, down from 3.0% a few weeks ago. The Cleveland Fed Inflation Nowcast forecasts 3.3% for April, about even with the March forecast. Mortgage rates have made another big move higher, up eight basis points last week, with the average 30-year fixed-rate mortgage now at 6.46%, according to FreddieMac. The next Federal Open Market Committee (FOMC) meeting is on April 29. Odds have pivoted from a rate cut to a rate hike, though they are low at 1% (suggesting no likely move of any kind). President Trump's nominee to be the next Fed chair, Kevin Warsh, is still making his way through the Congressional-approval process. Currently Chair Jerome Powell will remain on the FOMC. Taking a deeper dive into performance so far in 2026, a leading industrialized global stock market index, the ETF EFA, is up 2% year to date. The leading emerging market ETF (EEM) is up 3% year to date. U.S. growth stocks are down 10% year to date looking at ETF IWF, while value stocks (IWD) are up 1%. In other asset classes for the year to date, AGG bonds are down 1%, gold is up 7%, crude oil is up 92%, and Bitcoin is down 23%. The U.S. dollar is up 2%, tracking DXY. The VIX Volatility Index was at about 24 on Friday, above its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026 is Energy (+40%), Utilities (+7%), Materials (+7%), Consumer Staples (+6%), Industrials (+3%), Real Estate (+3%), Healthcare (-7%), Communication Services (-11%), Information Technology (-12%), Consumer Discretionary (-12%), and Financials (-13%). By comparison, the S&P 500 is down 4% year to date.

  • Medtronic Set for Key New Product Adoption in 2026

    One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: